For in vitro diagnostic use. Others Elecsys Anti-HCV II IVD Elecsys® Anti-HCV II CPS_000442 08 837 031 190 8 837 031 190 08837031190 8837031190 08837031190 Anti-HCV G2 Elecsys cobas e 200 V2 Elecsys Anti-HCV II 07613336166970 Reagents, kits 200 tests cobas e 411/601/602 true 08 837 058 190 8 837 058 190 08837058190 8837058190 08837058190 Anti-HCV G2 Elecsys E2G 300 V2 Elecsys Anti-HCV II 07613336166994 Reagents, kits 300 tests cobas e 402/801 true 03 290 379 190 3 290 379 190 03290379190 3290379190 03290379190 Anti-HCV PC Elecsys PreciControl Anti-HCV 04015630936946 Controls 16 × 1.30 mL cobas e 402/411/601/602/801 true 08 836 981 190 8 836 981 190 08836981190 8836981190 08836981190 Anti-HCV G2 Elecsys cobas e 100 V2 Elecsys Anti-HCV II 07613336166956 Reagents, kits 100 tests cobas e 411/601/602 true 08837031501 Elecsys Anti-HCV II en 2 FF00000006FBE10E FF0000000601E10E 08837031190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro qualitative detection of antibodies to hepatitis C virus (HCV) in human adult and pediatric (ages 18 months through 21 years) serum and plasma (potassium EDTA, lithium heparin, sodium heparin, and sodium citrate). Assay results, in conjunction with other laboratory results and clinical information, may be used to aid in the presumptive diagnosis of HCV infection in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis C infection. The test does not determine the state of infection or associated disease.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08837058501 Elecsys Anti-HCV II en 1 FF00000006005C0E FF00000006005C0E 08837058190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro qualitative detection of antibodies to hepatitis C virus (HCV) in human adult and pediatric (ages 18 months through 21 years) serum and plasma (potassium EDTA, lithium heparin, sodium heparin, and sodium citrate). Assay results, in conjunction with other laboratory results and clinical information, may be used to aid in the presumptive diagnosis of HCV infection in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis C infection. The test does not determine the state of infection or associated disease.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en ms_03290379190 PreciControl Anti-HCV en 13 FF0000000578060E FF0000000402A30E 03290379190 618 cobas e 411 2325 cobas e 602 2497 cobas e 801 9494 cobas e 402 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use PreciControl Anti‑HCV is used for quality control of the Elecsys Anti‑HCV II immunoassay on cobas e immunoassay analyzers. en 08836981501 Elecsys Anti-HCV II en 2 FF00000006FBE00E FF0000000601DF0E 08836981190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro qualitative detection of antibodies to hepatitis C virus (HCV) in human adult and pediatric (ages 18 months through 21 years) serum and plasma (potassium EDTA, lithium heparin, sodium heparin, and sodium citrate). Assay results, in conjunction with other laboratory results and clinical information, may be used to aid in the presumptive diagnosis of HCV infection in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis C infection. The test does not determine the state of infection or associated disease.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en

Immunoassay for the qualitative determination of antibodies against HCV

The hepatitis C virus is a leading cause of liver disease and a major healthcare concern, causing more deaths than all other reportable infectious diseases combined since 2013. ¹

An estimated 3.5 million people are living with chronic HCV infection in the US, with over 100,000 new cases and nearly 15,000 deaths reported in 2021. ² Due to the high rate of asymptomatic infections, clinical diagnosis is difficult and screening assays are of major importance.³

Though now a curable disease, only 40% of those living with chronic HCV are diagnosed, and less than a third of those diagnosed have received treatment.² Chronic HCV infection may lead to cirrhosis and hepatocellular carcinoma, therefore, early detection of antibodies to HCV is the first step in the management of chronic hepatitis and in the selection of patients needing treatment.⁴

Elecsys® Anti-HCV II is an immunoassay for the in vitro qualitative detection of antibodies to hepatitis C virus in human adult and pediatric samples.⁵

User Profile

Select your user profile

Elecsys^® Anti-HCV II

Immunoassay for the qualitative determination of antibodies against HCV